Skip to main content
HCPCS Q0139 · Level II · Part B drug

Q0139: ferumoxytol (Feraheme), ESRD on dialysis, HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q0139

Billing unit
1 MG
Ferumoxytol, esrd use
ASP payment limit
$0.331
October 2026; -10.5% vs July 2026
Practitioner MUE
510
MAI 3
OPPS status
SI K
APC 1485
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q0139 is the Level II code for Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis), billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $0.331 per billing unit, down 10.5% from July 2026. The practitioner MUE allows up to 510 units per date of service (MAI 3), so a full 510-unit day is $168.81 at the current limit. Under OPPS it carries status indicator K in APC 1485. Because the descriptor is specific to ESRD patients on dialysis, Medicare expects the drug inside the ESRD prospective payment bundle when furnished by the dialysis facility, and separate Part B billing applies only outside that setting. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names ferumoxytol: Q0138 (for non-ESRD use); A9574 (Ferabright from Azurity Pharmaceuticals Inc). The ASP crosswalk maps 2 NDCs to it, sold as Ferumoxytol, Feraheme by Sandoz Inc., Covis Pharma US, Inc. No current Billing and Coding Article lists Q0139, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q0139 at $0.331 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.37 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q0139
QuarterPayment limitPerCoinsurance
October 2026$0.3311 MG20%
July 2026$0.371 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 2 labelers to Q0139. Report the NDC in the claim's drug segment and bill the number of Q0139 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to Q0139
NDCDrug nameLabelerPackage sizeBilling units / package
00781-3154-01FerumoxytolSandoz Inc.17 × 1510
59338-0775-01FerahemeCovis Pharma US, Inc17 × 1510

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q0139. For practitioners the limit is 510 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q0139 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services5103 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital5103 Date of Service Edit: ClinicalPrescribing Information

MUE for Q0139 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q0139 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q0139 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q0139 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q0139 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q0139 carries status indicator K and is assigned to APC 1485, with a published national unadjusted payment of $0.331. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q0139 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $0.33 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q0139 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q0139

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q0139

What does HCPCS code Q0139 describe?

Q0139 is defined by CMS as "Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q0139 a CPT code?

No. Q0139 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as ferumoxytol (Feraheme); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q0139 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q0139 in October 2026?

The ASP-based payment limit is $0.331 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.37. Commercial payers use their own fee schedules.

How many units of Q0139 can be billed per day?

The practitioner Medically Unlikely Edit is 510 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q0139?

The October 2026 ASP crosswalk lists 2 NDCs from 2 labelers: Ferumoxytol (Sandoz Inc.); Feraheme (Covis Pharma US, Inc). For example NDC 00781-3154-01 (package size 17) equals 510 billing units of Q0139.

Does Q0139 have NCCI bundling edits?

No active practitioner PTP pairs list Q0139 as a column-1 or column-2 code in the v323r0 release.

Q0139 vs Q0138: what is the difference?

Both are HCPCS Level II codes whose descriptor names ferumoxytol. What sets Q0138 apart: for non-ESRD use. Q0139 is billed per 1 mg, limit $0.331, MUE 510; Q0138 is billed per 1 mg, limit $0.331, MUE 510. Report the code whose descriptor matches the product and setting in the record.

Q0139 vs A9574: what is the difference?

Both are HCPCS Level II codes whose descriptor names ferumoxytol. What sets A9574 apart: Ferabright from Azurity Pharmaceuticals Inc. Q0139 is billed per 1 mg, limit $0.331, MUE 510; A9574 is billed per 1 mg, OPPS rate $0.42. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.